Physician profile
Sanjay Gupta
NPI 1740238906
$1,859,160.29
in general payments reported to CMS, 2019-2025
31 companies · $379K in 2025
The $379K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $294K · 2020: $104K · 2021: $138K · 2022: $324K · 2023: $347K · 2024: $272K · 2025: $379K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $819K · Travel and Lodging: $108K · Consulting Fee: $52K · Food and Beverage: $19K · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $819,142.70 |
| Travel and Lodging | $107,667.72 |
| Consulting Fee | $52,265.50 |
| Food and Beverage | $19,039.92 |
| Education | $105.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $403,810.87 | 2019-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $392,541.40 | 2020-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $239,910.91 | 2019-2025 | Spravato, Invega Sustenna |
| Alkermes, INC. | $182,666.01 | 2019-2025 | Aristada, Aristada Initio, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $179,346.53 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $135,223.34 | 2024-2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $90,535.85 | 2019-2025 | Uzedy, Austedo |
| Acadia Pharmaceuticals INC | $65,706.45 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $42,834.26 | 2024-2025 | Cobenfy |
| Indivior INC. | $37,278.87 | 2019-2023 | Perseris |
| Abbvie INC. | $34,876.03 | 2021-2024 | |
| Allergan, INC. | $30,644.95 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $20,116.46 | 2019-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $2,666.49 | 2019-2021 | |
| Eisai INC. | $139.73 | 2020-2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $132.71 | 2020-2023 | Neurostar Tms Therapy System |
| Janssen Scientific Affairs, LLC | $131.01 | 2025 | Invega Sustenna |
| Axsome Therapeutics, INC. | $130.35 | 2024-2025 | Auvelity |
| Avanir Pharmaceuticals, INC. | $82.79 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $71.64 | 2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $71.57 | 2020-2022 | |
| Stryker Corporation | $41.62 | 2019 | |
| Merck Sharp & Dohme LLC | $38.96 | 2022 | |
| Lundbeck LLC | $37.47 | 2019-2024 | Rexulti |
| Arbor Pharmaceuticals, INC. | $30.48 | 2021 | |
| Almatica Pharma LLC | $25.62 | 2022 | |
| Jazz Pharmaceuticals INC. | $24.07 | 2021 | |
| Noven Therapeutics, LLC | $17.07 | 2024 | Xelstrym, Secuado |
| Alexion Pharmaceuticals, INC. | $13.81 | 2020 | |
| Shire North American Group INC | $12.97 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5,918.05 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.